W. Michael Kavanaugh

机构：CytomX Therapeutics (United States) · ORCID：0000-0002-3938-0608

发表论文 43 篇 · 总被引 2765 次 · h-index 19

代表论文

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors (2015 · Annals of Oncology · 被引 94)
A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity (2022 · Cancer Research · 被引 59)
Antibody prodrugs for cancer (2019 · Expert Opinion on Biological Therapy · 被引 53)
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic (2021 · Proceedings of the National Academy of Sciences · 被引 36)
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate (2022 · Molecular Cancer Therapeutics · 被引 35)
Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes (2020 · Scientific Reports · 被引 34)